Noninvasive Treatment of Alzheimer's Disease with Scintillating Nanotubes

Abstract

AbstractEffective and accessible treatments for Alzheimer's disease (AD) are urgently needed. Soluble Aβ oligomers are identified as neurotoxic species in AD and targeted in antibody‐based drug development to mitigate cognitive decline. However, controversy exists concerning their efficacy and safety. In this study, an alternative strategy is proposed to inhibit the formation of Aβ oligomers by selectively oxidizing specific amino acids in the Aβ sequence, thereby preventing its aggregation. Targeted oxidation is achieved using biocompatible and blood‐brain barrier‐permeable multicomponent nanoscintillators that generate singlet oxygen upon X‐ray interaction. Surface‐modified scintillators interact selectively with Aβ and, upon X‐ray irradiation, inhibit the formation of neurotoxic aggregates both in vitro and in vivo. Feeding transgenic Caenorhabditis elegans expressing human Aβ with the nanoscintillators and subsequent irradiation with soft X‐ray reduces Aβ oligomer levels, extends lifespan, and restores memory and behavioral deficits. These findings support the potential of X‐ray‐based therapy for AD and warrant further development.